Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials.

Sites, mechanisms of action, and differentiation of calcium channel antagonists.

Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Is renal protection with calcium antagonists possible?

Clinical effects and mechanism of action of sumatriptan in migraine.

Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine.

Coeliac disease: A review of the causative agents and their possible mechanisms of action.

Possible mechanisms of fullerene C₆₀ antioxidant action.

PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Antimutagenic compounds and their possible mechanisms of action.

How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT).

Natriuretic effects of calcium antagonists. Clinical implications.

Experimental and clinical action of thromboxane A2 receptor antagonists.

Epigone migraine vertigo (EMV): a late migraine equivalent.

A review of possible mechanisms of action of the antirheumatic drug, alclofenac.

Oxidized low-density lipoproteins in atherogenesis: possible mechanisms of action.

Pharmacological versus non-pharmacological prophylaxis of recurrent migraine headache: a meta-analytic review of clinical trials.

Mechanisms of action of hisamine and histamine antagonists on the glomerular microcirculation in the rat.

Calcium, calcium channels, and calcium channel antagonists.

Mechanisms and direction of allocation bias in randomised clinical trials.

Calcium supplementation and bone loss: a review of controlled clinical trials.

Calcium antagonists and hypercalcaemia.

CGRP mechanism antagonists and migraine management.

5-HT2 receptor antagonists and migraine therapy.

Suggest Documents

Sites, mechanisms of action, and differentiation of calcium channel antagonists.

Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Is renal protection with calcium antagonists possible?

Clinical effects and mechanism of action of sumatriptan in migraine.

Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine.

Coeliac disease: A review of the causative agents and their possible mechanisms of action.

Possible mechanisms of fullerene C₆₀ antioxidant action.

PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Antimutagenic compounds and their possible mechanisms of action.

How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT).

Natriuretic effects of calcium antagonists. Clinical implications.

Experimental and clinical action of thromboxane A2 receptor antagonists.

Epigone migraine vertigo (EMV): a late migraine equivalent.

A review of possible mechanisms of action of the antirheumatic drug, alclofenac.

Oxidized low-density lipoproteins in atherogenesis: possible mechanisms of action.

Pharmacological versus non-pharmacological prophylaxis of recurrent migraine headache: a meta-analytic review of clinical trials.

Mechanisms of action of hisamine and histamine antagonists on the glomerular microcirculation in the rat.

Calcium, calcium channels, and calcium channel antagonists.

Mechanisms and direction of allocation bias in randomised clinical trials.

Calcium supplementation and bone loss: a review of controlled clinical trials.

Calcium antagonists and hypercalcaemia.

CGRP mechanism antagonists and migraine management.

5-HT2 receptor antagonists and migraine therapy.

Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials.

Recommend Documents

Follow Us